Showing 5651-5660 of 8544 results for "".
- New Agreement Opens Premier Networks to TeleVox Techhttps://practicaldermatology.com/news/televox-and-premier-inc-announce-national-patient-engagement-agreement/2476115/TeleVox has announced a national group purchasing agreement with Premier, Inc. effective September 1, 2025, permiting Premier members to access negotiated pricing and terms for TeleVox offerings, including Digital Front Door, Appointment Management, Digital Care P
- New: Researchers ID Polygenic Signature in Sporadic HShttps://practicaldermatology.com/news/researchers-identify-polygenic-signature-in-sporadic-hs/2476099/Researchers on a new study proposed a polygenic score (PGS) model that points to a genetic contribution to susceptibility in sporadic hidradenitis suppurativa (spHS). Publishing in the Journal of Investigative Dermatology
- Dr. Ted Rosen on JAK Inhibitors for Refractory Granulomatous and Autoimmune Dermatoseshttps://practicaldermatology.com/news/Dr-Ted-Rosen-JAK-Inhibitors-Refractory-Granulomatous-Autoimmune-Dermatoses/2476038/The role of JAK inhibitors in diseases characterized by chronic macrophage–T-cell interactions continues to grow, Theodore Rosen, MD, said at the DEF Essential Resource Meeting 2025 (DERM2025). The discussion focused on granuloma annulare (GA), sarcoidosis, lichen planus (LP), and lupus erythemat
- Dr. Ted Rosen Highlights Oral Lesions in Dermatologyhttps://practicaldermatology.com/news/Dr-Ted-Rosen-Highlights-Oral-Lesions-Dermatology/2476037/Oral lesions represent a diagnostic challenge in dermatology due to their limited morphological variation and overlapping features across conditions. At the DEF Essential Resource Meeting 2025 (DERM2025), Theodore Rosen, MD, reviewed a broad spectrum of oral pathologies, from benign pigmentations
- Study: Ustekinumab Shows Durability in Real-World Psoriasis Biologic Sequencing Studyhttps://practicaldermatology.com/news/study-ustekinumab-shows-durability-in-real-world-psoriasis-biologic-sequencing-study/2476000/Ustekinumab (Stelara) was associated with the longest treatment duration among biologics used for moderate-to-severe psoriasis, according to results from a recent retrospective real-world analysis. Researchers evaluated health
- 2025 ASDS Survey: 70% of Consumers Considering Cosmetic Procedureshttps://practicaldermatology.com/news/2025-asds-survey-70-of-consumers-considering-cosmetic-procedures/2475889/Seventy percent of Americans are considering a cosmetic dermatologic procedure, trusting board-certified dermatologists as top influencers in patient decision-making, according to the 2025 Consumer Survey on Cosmetic Dermatologic Procedures by the American Society
- FDA Greenlights First Treatment for Chronic Hand Eczema in Adultshttps://practicaldermatology.com/news/fda-approves-first-treatment-for-chronic-hand-eczema-in-adults/2475816/The US Food and Drug Administration (FDA) has approved ANZUPGO® (delgocitinib) cream, making it the first and only treatment approved for adults with moderate-to-severe chronic hand eczema (CHE) who are unresponsive to topical corticosteroids or for those unsuitabl
- Analysis: Arnica’s Popularity on Social Not Supported by Data for Post-Procedure Recoveryhttps://practicaldermatology.com/news/analysis-arnicas-popularity-on-social-media-outpaces-scientific-support-for-post-procedure-recovery/2475830/Social media users and health care professionals frequently endorse Arnica montana for reducing bruising and swelling following aesthetic injectables, but a recent analysis shows scientific support for its use may be lacking.
- Long-Term Ixekizumab Use Not Linked to Increased Cancer Risk: Analysishttps://practicaldermatology.com/news/long-term-ixekizumab-use-not-linked-to-increased-cancer-risk/2475704/Long-term treatment with ixekizumab (IXE) for psoriasis, psoriatic arthritis, and axial spondyloarthritis was not associated with increased risk of malignant neoplasms, according to a new analysis of pooled data from 25 randomized clinical trials.
- LEQSELVI™ Launches in U.S. as Oral Treatment for Severe Alopecia Areatahttps://practicaldermatology.com/news/leqselvitm-launches-in-us-as-oral-treatment-for-severe-alopecia-areata/2475680/Sun Pharmaceutical Industries Ltd. announced the U.S. commercial availability of LEQSELVI™ (deuruxolitinib), an oral Janus kinase (JAK) inhibitor indicated for the treatment of adults with severe alopecia areata, according to a press release from the manufacturer.